Pacira BioSciences (PCRX) Gross Profit (2010 - 2026)

Pacira BioSciences' Gross Profit history runs 17 years deep, the most recent figure standing at $141.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 4.71% year-over-year to $141.0 million; the TTM figure through Mar 2026 stood at $583.0 million (up 6.88% YoY), while the FY2025 annual figure was $576.7 million, up 8.69% from the prior year.
• Gross Profit was $141.0 million for Q1 2026 at Pacira BioSciences, down from $156.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $156.6 million in Q4 2025 to a low of -$541.5 million in Q4 2022.
• Historically, Gross Profit has averaged $91.4 million across 5 years, with a median of $129.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Profit sank 550.57% in 2022, then surged 124.66% in 2023.
• A 5-year view of Gross Profit shows it stood at -$541.5 million in 2022, then soared by 124.66% to $133.6 million in 2023, then advanced by 10.34% to $147.4 million in 2024, then climbed by 6.25% to $156.6 million in 2025, then fell by 9.97% to $141.0 million in 2026.
• The last three Gross Profit figures came in at $141.0 million (Q1 2026), $156.6 million (Q4 2025), and $145.2 million (Q3 2025), per Business Quant data.